Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21132564 | 0.82 | NPC1 (0.35) | NPC1RAB9A | |
| SCHEMBL31148642 | 0.77 | KMT2A (0.35) | NPC1RAB9A | |
| SCHEMBL31148580 | 0.77 | NPC1 (0.42) | NPC1RAB9A | |
| SCHEMBL1674091 | 0.74 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL31148698 | 0.74 | LMNA (0.32) | NPC1RAB9A | |
| SCHEMBL28798823 | 0.74 | MEN1 (0.33) | NPC1RAB9A | |
| SCHEMBL31148787 | 0.73 | MAPK1 (0.39) | NPC1RAB9AALDH1A1TSHR | |
| SCHEMBL25004287 | 0.73 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL25204833 | 0.72 | TARBP2 (0.38) | NPC1ALDH1A1ALOX15 | |
| SCHEMBL25207863 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694980-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF NLRP3 | Takeda Pharmaceutical Company Limited (JP) | 2026-02-18 | — | — | EP | disclosed |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| WO-2025128873-A1 | HETEROCYCLIC PYRIDINONE COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2024214046-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF NLRP3 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-17 | — | — | WO | disclosed |
| CN-117730080-A | Pyridopyrimidinone derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2023086800-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023030215-A1 | PYRIDOPYRIMIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2023-03-09 | — | — | WO | disclosed |
| CN-115611888-A | Pyridopyrimidinone derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| WO-2011014535-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011014535-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |
| EP-1893585-A1 | PROCESS FOR THE PREPARATION OF N-[4-(4-FLUOROPHENYL)-5-FORMYL-6-ISOPROPYL-PYRIMIDIN-2-YL]-N-METHYLMETHANESULFONAMIDE | Fermion Oy (FI) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006128954-A1 | PROCESS FOR THE PREPARATION OF N-[4-(4-FLUOROPHENYL)-5-FORMYL-6-ISOPROPYL-PYRIMIDIN-2-YL]-N-METHYLMETHANESULFONAMIDE | FERMION OY (FI) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | NPC1 335/4885RAB9A 2172/4885ALDH1A1 1956/4885 |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | NPC1 335/4885RAB9A 2172/4885ALDH1A1 1956/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | NPC1 290/4885RAB9A 700/4885ALDH1A1 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.